Piscataway, NJ, October 10, 2023–Camber Pharmaceuticals is pleased to announce the addition of Gabapentin Capsules, USP to its current portfolio.
Gabapentin Capsules, USP are indicated for:
- Postherpetic neuralgia in adults
- Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy
Gabapentin Capsules, USP are available in 100, 300, and 400 mg strengths in 500 count bottles.
To find out more about Gabapentin Capsules, USP, please visit www.camberpharma.com
Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dose manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers and improving quality of life through cost-effective medications.
